Literature DB >> 28207655

Internally Randomized Control Trial of Radiation Exposure Using Ultra-low Radiation Imaging Versus Traditional C-arm Fluoroscopy for Patients Undergoing Single-level Minimally Invasive Transforaminal Lumbar Interbody Fusion.

Timothy Y Wang1, S Harrison Farber1, Scott S Perkins1, Adam G Back1, Sarah A Byrd1, Debbie Chi1, David Vincent2, Isaac O Karikari1.   

Abstract

STUDY
DESIGN: Randomized controlled trial.
OBJECTIVE: To compare radiation exposure between ultra-low radiation imaging (ULRI) with image enhancement and standard-dose fluoroscopy for patients undergoing minimally invasive transforaminal lumbar interbody fusion (MIS TLIF). SUMMARY OF BACKGROUND DATA: Although the benefits of MIS are lauded by many, there is a significant amount of radiation exposure to surgeon and operating room personnel. Our goal with this work was to see if by using ultra-low dose radiation settings coupled with image enhancement, this exposure could be minimized.
METHODS: An institutional review board approved, prospective, internally randomized controlled trial was performed comparing ultra-low dose settings coupled with image enhancement software to conventional fluoroscopic imaging. In this study, each patient served as their own control, randomly assigning one side of MIS-TLIF for cannulation and K-wire placement using each imaging modality. Further, the case was also randomly divided into screw placement and cage placement/final images to allow further comparisons amongst patients. Radiation production from the C-arm fluoroscope and radiation exposure to all operating room personnel were recorded.
RESULTS: Twenty-four patients were randomly assigned to undergo a single level MIS-TLIF. In no case was low radiation imaging abandoned, and no patient had a neurologic decline or required hardware repositioning. Everyone in the operating room-the physician, scrub nurse, circulator, and anesthesiologist-all benefited with 61.6% to 83.5% reduction in radiation exposure during cannulation and K-wire placement to screw insertion aided by ULRI. In every case but the anesthesiologist dose, this was statistically significant (P < 0.05). This benefit required no additional time (P = 0.78 for K-wire placement).
CONCLUSION: ULRI, when aided by image enhancement software, affords the ability for all parties in the operating room to substantially decrease their radiation exposure compared with standard-dose C-arm fluoroscopy without adding additional time or an increased complication rate. LEVEL OF EVIDENCE: 2.

Entities:  

Mesh:

Year:  2017        PMID: 28207655     DOI: 10.1097/BRS.0000000000001720

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  5 in total

1.  Accuracy of minimally invasive percutaneous thoracolumbar pedicle screws using 2D fluoroscopy: a retrospective review through 3D CT analysis.

Authors:  Mark J Winder; Paul M Gilhooly
Journal:  J Spine Surg       Date:  2017-06

2.  Minimal-invasive revision of adjacent level disease after MIS deformity surgery.

Authors:  Nils Hansen-Algenstaedt; Melanie Liem; SalahAddeen O Khalifah; Johannes Holz; Alf Giese
Journal:  Eur Spine J       Date:  2017-12       Impact factor: 3.134

Review 3.  Intraoperative image guidance for lateral position surgery.

Authors:  Peter R Swiatek; Michael H McCarthy; Joseph Weiner; Shivani Bhargava; Avani S Vaishnav; Sravisht Iyer
Journal:  Ann Transl Med       Date:  2021-01

Review 4.  Narrative review of intraoperative image guidance for transforaminal lumbar interbody fusion.

Authors:  Joseph A Weiner; Michael H McCarthy; Peter Swiatek; Philip K Louie; Sheeraz A Qureshi
Journal:  Ann Transl Med       Date:  2021-01

5.  Distinct fusion intersegmental parameters regarding local sagittal balance provide similar clinical outcomes: a comparative study of minimally invasive versus open transforaminal lumbar interbody fusion.

Authors:  Fuping Li; Chen Li; Xin Xi; Zhili Zeng; Bin Ma; Ning Xie; Hang Wang; Yan Yu; Liming Cheng
Journal:  BMC Surg       Date:  2020-05-12       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.